Status:
UNKNOWN
Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy
Lead Sponsor:
Al-Azhar University
Conditions:
Hepatic Encephalopathy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The aim of this study is to evaluate the efficacy of lactoferrin as an adjunct therapy in improving clinical symptoms and laboratory indices in individuals with hepatic encephalopathy.
Detailed Description
Nonabsorbable disaccharides, such as lactulose or lactitol, decrease the absorption of ammonia and are considered a first-line treatment for hepatic encephalopathy. Antimicrobial therapy also is a par...
Eligibility Criteria
Inclusion
- 18 years and older.
- Grade I and II hepatic encephalopathy.
Exclusion
- Pregnant and breastfeeding women.
- Grade III and IV hepatic encephalopathy.
- Individuals confirmed to be allergic to milk protein
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06072521
Start Date
October 1 2023
End Date
October 1 2024
Last Update
October 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National hepatology and tropical medicine research institute
Cairo, Egypt